[1] Xu X, Wang G, Chen N, Lu T, Nie S, Xu G, Zhang P, Luo Y, Wang Y, Wang X, Schwartz J, Geng J, Hou FF. Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China. J Am Soc Nephrol. 2016; 27(12):3739–3746.
[2] Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G. Prevalence and control of diabetes in Chinese adults. J Am Med Assoc. 2013; 310 (9):948–958.
[3] Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822.
[4] Liu S, Guo Q, Han H, Cui P, Liu X, Miao L, Zou H, Sun G. Clinicopathological characteristics of non-diabetic renal disease in patients with type 2 diabetes mellitus in a northeastern Chinese medical center: a retrospective analysis of 273 cases. Int Urol Nephrol. 2016; 48(10):1691–1698.
[5] Horvatic I, Tisljar M, Kacinari P, Matesic I, Bulimbasic S, Galesic Ljubanovic D, Katic T, Kristovic D, Galesic K. Non-diabetic renal disease in Croatian patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014; 104(3):443–450.
[6] Chang TI, Park JT, Kim JK, Kim SJ, Oh HJ, Yoo DE, Han SH, Yoo TH, Kang SW. Renal outcomes in patients with type 2 diabetes with or without coexisting non-diabetic renal disease. Diabetes Res Clin Pract. 2011; 92(2):198–204.
[7] Erdogmus S, Kiremitci S, Celebi ZK, Akturk S, Duman N, Ates K, Erturk S, Nergizoglu G, Kutlay S, Sengul S, Ensari A, Keven K. Non-Diabetic Kidney Disease in Type 2 Diabetic Patients: Prevalence, Clinical Predictors and Outcomes. Kidney Blood Press Res. 2017;42(5):886–893.
[8] Sharma SG, Bomback AS, Radhakrishnan J, Herlitz LC, Stokes MB, Markowitz GS, D’Agati VD. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol. 2013; 8(10):1718–24.
[9] Liu D, Huang T, Chen N, Xu G, Zhang P, Luo Y, Wang Y, Lu T, Wang L, Xiong M, Geng J, Nie S. The modern spectrum of biopsy-proven renal disease in Chinese diabetic patients-a retrospective descriptive study. Peer J. 2018;6: e4522.
[10] Johannesdottir SA1, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JO, Ehrenstein V, Vandenbroucke JP, Pedersen L, Sørensen HT. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study. JAMA Intern Med. 2013; 173(9):743–752.
[11] Cattran DC, Feehally J, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, Floege J, Nachman PH, Gipson DS, Praga M, Glassock RJ, Radhakrishnan J, Hodson EM, Rovin BH, J Jha V, Troyanov S, Li PKT, Wetzels JFM. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012; 2(2):139–274.
[12] American Diabetes Association. Standards of Medical Care in Diabetes–2019. Diabetes Care. 2019; 42(Suppl 1): S184-S186.
[13] Levey AS, Stevens LA, Schmid CH, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150: 604–612.
[14] Fassett RG, Horgan BA, Mathew TH: Detection of glomerular bleeding by phase contrast microscopy. Lancet. 1982; 1:1432–1434.
[15] Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J. Prevalence of Diabetes among Men and Women in China. N Engl J Med. 2010; 362 (25):1090–1101.
[16] Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z, Li Y, Yeung RO, Wang J, Matsushita K, Coresh J, Zhao MH, Wang H. Trends in Chronic Kidney Disease in China. N Engl J Med. 2016; 375(9):905–906.
[17] Toth-Manikowski S, Atta MG. Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. J Diabetes Res. 2015; 2015:697010.
[18] Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361–377.
[19] Qian Y, Zuo K, Li S, Zeng C, Liu Z, Wu Y. Membranous nephropathy occurring with type 2 diabetes mellitus. Clin Nephrol. 2017; 87(3):140–146.
[20] Gauci R, Hunter M, Bruce DG, Davis WA, Davis TME. Anemia complicating type 2 diabetes: Prevalence, risk factors and prognosis. J Diabetes Complications. 2017; 31(7):1169–1174.
[21] Mehdi U, Toto RD. Anemia, Diabetes, and Chronic Kidney Disease. Diabetes care. 2009, 32(7):1320–1326.
[22] Jun JH, Song JW, Shin EJ, Kwak YL, Choi N, Shim JK. Ethyl pyruvate is renoprotective against ischemia-reperfusion injury under hyperglycemia. J Thorac Cardiovasc Surg. 2018,155(4):1650–1658.
[23] Cherney DZ, Scholey JW, Miller JA. Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev. 2008,4(4):280–90.
[24] Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V. A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy. J Am Soc Nephrol. 2007;18(6):1899–1904.
[25] Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant. 2010;25(1):129–136.
[26] Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Harada A. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant. 2009;24(10):3082–3088.
[27] Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF. Mycophenolate Mofetil in Idiopathic Membranous Nephropathy: A Clinical Trial with Comparison to a Historic Control Group Treated with Cyclophosphamide. Am J Kidney Dis. 2007; 50(2):248–256.
[28] Goumenos DS, Katopodis KP, Passadakis P, Vardaki E, Liakopoulos V, Dafnis E, Stefanidis I, Vargemezis V, Vlachojannis JG, Siamopoulos KC. Corticosteroids and Ciclosporin A in Idiopathic Membranous Nephropathy: Higher Remission Rates of Nephrotic Syndrome and Less Adverse Reactions than after Traditional Treatment with Cytotoxic Drugs. Am J Nephrol. 2007; 27(3):226–231.
[29] Yu X, Ruan L, Qu Z, Cui Z, Zhang Y, Wang X, Meng L, Liu X, Wang F, Zhang Y, Liu G, Yang L. Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety. Ren Fail. 2017; 39(1):688–697.
[30] Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O’Donoghue D, Boulton-Jones M, Mathieson PW. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013; 381(9868):744–751.
[31] Li MX, Yu YW, Zhang ZY, Zhao HD, Xiao FL. Administration of low-dose cyclosporine alone for the treatment of elderly patients with membranous nephropathy. Genet Mol Res. 2015; 14(1):2665–2673.
[32] Christiansen CF, Schmidt M, Lamberg AL, Horváth-Puhó E, Baron JA, Jespersen B, Sørensen HT. Kidney disease and risk of venous thromboembolism: a nationwide population‐based case‐control study. J Thromb Haemost. 2014; 12(9):1449–1454.
[33] Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN. Venous Thromboembolism in Patients with Membranous Nephropathy. Clin J Am Soc Nephrol. 2012; 7(1):43–51.
[34] Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract. 2018; 139:203–220.
[35] Burroughs TE, Lentine KL, Takemoto SK, Swindle J, Machnicki G, Hardinger K, Brennan DC, Irish WD, Schnitzler MA. Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol.2007;2(3):517–523.